Directed Delivery of Growth Factors to the CNS

生长因子定向输送至中枢神经系统

• 批准号: 6934761
• 负责人: ANDREW BAIRD
• 金额: $ 29.02万
• 依托单位: TERA BIOTECHNOLOGY CORPORATION
• 依托单位国家: 美国
• 财政年份: 2005
• 资助国家: 美国
• 起止时间: 2005-07-15 至 2006-06-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6934761
• 关键词: 6 hydroxydopamine; Parkinson' s disease; autoradiography; biotechnology; biotherapeutic agent; blood brain barrier; brain disorder chemotherapy; cell proliferation; combinatorial chemistry; disease /disorder model; drug delivery systems; drug design /synthesis /production; drug screening /evaluation; epidermal growth factor; immunocytochemistry; inhalation drug administration; laboratory rat; nerve stem cell; nervous system regeneration; neuropharmacologic agent; nonhuman therapy evaluation; phage display; pharmacokinetics; transforming growth factors; western blottings

DESCRIPTION (provided by applicant): Certain proteins, like growth factors have significant potential to treat neurodegenerative disease. Accordingly, it should be possible to stimulate the growth of endogenous progenitor stem cells so that they could enhance the natural course of injury repair. Unfortunately, the blood brain barrier forms a significant hurdle that limits the clinical utility of most peptides. We propose to apply principles of medicinal biology and combinatorial pharmacology to improve the delivery of growth factors to the brain and describe a comprehensive strategy to address a major problem in the development of CNS biotherapeutics: drug delivery to the brain.

描述（由申请人提供）：某些蛋白质，如生长因子，具有治疗神经退行性疾病的巨大潜力。因此，应该有可能刺激内源性祖干细胞的生长，从而增强损伤修复的自然过程。不幸的是，血脑屏障形成了限制大多数肽的临床应用的重大障碍。我们建议应用医学生物学和组合药理学原理来改善生长因子向大脑的输送，并描述一种综合策略来解决中枢神经系统生物治疗药物开发中的一个主要问题：向大脑的药物输送。